US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
GB1429184A
(en)
|
1972-04-20 |
1976-03-24 |
Allen & Hanburys Ltd |
Physically anti-inflammatory steroids for use in aerosols
|
US4044126A
(en)
|
1972-04-20 |
1977-08-23 |
Allen & Hanburys Limited |
Steroidal aerosol compositions and process for the preparation thereof
|
USRE28819E
(en)
|
1972-12-08 |
1976-05-18 |
Syntex (U.S.A.) Inc. |
Dialkylated glycol compositions and medicament preparations containing same
|
US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4358603A
(en)
|
1981-04-16 |
1982-11-09 |
Syntex (U.S.A.) Inc. |
Acetal stabilized prostaglandin compositions
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
EP0092918B1
(en)
|
1982-04-22 |
1988-10-19 |
Imperial Chemical Industries Plc |
Continuous release formulations
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
US4663281A
(en)
|
1984-03-22 |
1987-05-05 |
Mass Institute Of Technology |
Enhanced production of proteinaceous materials in eucaryotic cells
|
US4789633A
(en)
|
1984-04-19 |
1988-12-06 |
University Of Tennessee Research Corporation |
Fused liposome and acid induced method for liposome fusion
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
GB8720833D0
(en)
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
AU631802B2
(en)
|
1988-06-14 |
1992-12-10 |
Cetus Oncology Corporation |
Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
EP1892296A1
(en)
|
1988-09-02 |
2008-02-27 |
Dyax Corporation |
Generation and selection of recombinant varied binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
US5734033A
(en)
|
1988-12-22 |
1998-03-31 |
The Trustees Of The University Of Pennsylvania |
Antisense oligonucleotides inhibiting human bcl-2 gene expression
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
ZA902949B
(en)
|
1989-05-05 |
1992-02-26 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
ATE152174T1
(de)
|
1989-09-20 |
1997-05-15 |
Abbott Lab |
Verfahren zur herstellung von fusionsproteinen
|
AU6430190A
(en)
|
1989-10-10 |
1991-05-16 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
EP0550436A1
(en)
|
1989-11-06 |
1993-07-14 |
Alkermes Controlled Therapeutics, Inc. |
Protein microspheres and methods of using them
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
US5780225A
(en)
|
1990-01-12 |
1998-07-14 |
Stratagene |
Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
|
WO1991010737A1
(en)
|
1990-01-11 |
1991-07-25 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
CA2077348A1
(en)
|
1990-03-02 |
1991-09-03 |
Stephen D. Gillies |
Antibody constructs with enhanced binding affinity
|
DE69127749T2
(de)
|
1990-03-20 |
1998-04-16 |
Univ Columbia |
Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
|
IT1246382B
(it)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
EP0542810A1
(en)
|
1990-08-02 |
1993-05-26 |
B.R. Centre Limited |
Methods for the production of proteins with a desired function
|
DK0546073T3
(da)
|
1990-08-29 |
1998-02-02 |
Genpharm Int |
Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
DK0574395T3
(da)
|
1990-11-09 |
2002-10-07 |
Stephen D Gillies |
Cytokin-immunkonjugater
|
WO1992008801A1
(en)
|
1990-11-09 |
1992-05-29 |
Abbott Laboratories |
Bridging antibody fusion constructs
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
ATE145428T1
(de)
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
CA2108147C
(en)
|
1991-04-10 |
2009-01-06 |
Angray Kang |
Heterodimeric receptor libraries using phagemids
|
DE69232706T2
(de)
|
1991-05-01 |
2002-11-28 |
Jackson H M Found Military Med |
Verfahren zur behandlung infektiöser respiratorischer erkrankungen
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
GB9112536D0
(en)
|
1991-06-11 |
1991-07-31 |
Celltech Ltd |
Chemical compounds
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
AU2238292A
(en)
|
1991-06-14 |
1993-01-12 |
Xoma Corporation |
Microbially-produced antibody fragments and their conjugates
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
WO1993011236A1
(en)
|
1991-12-02 |
1993-06-10 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
US5766886A
(en)
|
1991-12-13 |
1998-06-16 |
Xoma Corporation |
Modified antibody variable domains
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US6271242B1
(en)
|
1992-02-10 |
2001-08-07 |
Bristol-Myers Squibb Co. |
Method for treating cancer using a tyrosine protein kinase inhibitor
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6010715A
(en)
|
1992-04-01 |
2000-01-04 |
Bertek, Inc. |
Transdermal patch incorporating a polymer film incorporated with an active agent
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
US6024975A
(en)
|
1992-04-08 |
2000-02-15 |
Americare International Diagnostics, Inc. |
Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
DK1589107T3
(da)
|
1992-08-21 |
2010-04-26 |
Univ Bruxelles |
Immonuglobuliner uden lette kæder
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5441050A
(en)
|
1992-12-18 |
1995-08-15 |
Neoprobe Corporation |
Radiation responsive surgical instrument
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
ATE281469T1
(de)
|
1993-03-25 |
2004-11-15 |
Merck & Co Inc |
Inhibitor des wachstumsfaktors für gefäss- endothelzellen
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
ES2162863T3
(es)
|
1993-04-29 |
2002-01-16 |
Unilever Nv |
Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
|
WO1995002420A2
(en)
|
1993-07-15 |
1995-01-26 |
Cancer Research Campaign Technology Ltd. |
Prodrugs of protein tyrosine kinase inhibitors
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
EP0733070A1
(en)
|
1993-12-08 |
1996-09-25 |
Genzyme Corporation |
Process for generating specific antibodies
|
US5925376C1
(en)
|
1994-01-10 |
2001-03-20 |
Madalene C Y Heng |
Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
|
US5618709A
(en)
|
1994-01-14 |
1997-04-08 |
University Of Pennsylvania |
Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
|
DK0744958T3
(da)
|
1994-01-31 |
2003-10-20 |
Univ Boston |
Polyklonale antistofbiblioteker
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
US5516637A
(en)
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
CZ25697A3
(en)
|
1994-07-29 |
1997-09-17 |
Smithkline Beecham Plc |
Novel compounds
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
US5911995A
(en)
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
US5587459A
(en)
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
EP0805678B1
(en)
|
1995-01-05 |
2003-10-29 |
THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN |
Surface-modified nanoparticles and method of making and using same
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
CA2210656C
(en)
|
1995-01-17 |
2011-07-05 |
Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
GB9501567D0
(en)
|
1995-01-26 |
1995-03-15 |
Pharmacia Spa |
Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
|
US5998596A
(en)
|
1995-04-04 |
1999-12-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibition of protein kinase activity by aptameric action of oligonucleotides
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US5983134A
(en)
|
1995-04-23 |
1999-11-09 |
Electromagnetic Bracing Systems Inc. |
Electrophoretic cuff apparatus drug delivery system
|
DE69637481T2
(de)
|
1995-04-27 |
2009-04-09 |
Amgen Fremont Inc. |
Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
|
AU2466895A
(en)
|
1995-04-28 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
ES2268705T3
(es)
|
1995-06-01 |
2007-03-16 |
Kishimoto, Tadamitsu |
Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
GB9515975D0
(en)
|
1995-08-04 |
1995-10-04 |
Zeneca Ltd |
Chemical compounds
|
US6167301A
(en)
|
1995-08-29 |
2000-12-26 |
Flower; Ronald J. |
Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
|
WO1997007788A2
(en)
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics, Inc. |
Composition for sustained release of an agent
|
US5863904A
(en)
|
1995-09-26 |
1999-01-26 |
The University Of Michigan |
Methods for treating cancers and restenosis with P21
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
US6576754B2
(en)
|
1995-11-09 |
2003-06-10 |
Dana-Farber Cancer Institute |
CD100 antigen and uses therefor
|
US6127366A
(en)
|
1995-11-22 |
2000-10-03 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
TR199800825T2
(xx)
|
1995-12-08 |
1998-08-21 |
Janssen Pharmaceutica N.V. |
Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
US5958769A
(en)
|
1996-01-18 |
1999-09-28 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for mediating cell cycle progression
|
JP2978435B2
(ja)
|
1996-01-24 |
1999-11-15 |
チッソ株式会社 |
アクリロキシプロピルシランの製造方法
|
US6066738A
(en)
|
1996-01-30 |
2000-05-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6090948A
(en)
|
1996-01-30 |
2000-07-18 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
PT885002E
(pt)
|
1996-03-04 |
2011-07-14 |
Massachusetts Inst Technology |
Materiais e métodos para aumento da internalização celular
|
WO1997033899A1
(en)
|
1996-03-14 |
1997-09-18 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule i
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
EP0904278A4
(en)
|
1996-03-22 |
1999-09-15 |
Human Genome Sciences Inc |
MOLECULE II INDUCER OF APOPTOSIS
|
US5883105A
(en)
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5891889A
(en)
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6063930A
(en)
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US6080870A
(en)
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US6300501B1
(en)
|
1996-05-22 |
2001-10-09 |
Warner-Lambert Company |
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
US5648239A
(en)
|
1996-06-21 |
1997-07-15 |
Incyte Pharmaceuticals, Inc. |
Human camp-dependent protein kinase inhibitor homolog
|
CA2258518C
(en)
|
1996-06-27 |
2011-11-22 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Recognition molecules interacting specifically with the active site or cleft of a target molecule
|
EP0907649A1
(en)
|
1996-06-27 |
1999-04-14 |
Pfizer Inc. |
Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
|
NL1003648C2
(nl)
|
1996-07-19 |
1998-01-21 |
Carino Cornelis Sunderman |
Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
|
US6028176A
(en)
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
DK0956865T4
(da)
|
1996-08-12 |
2010-11-22 |
Mitsubishi Tanabe Pharma Corp |
Medikamenter omfattende Rho-kinaseinhibitor
|
US5985317A
(en)
|
1996-09-06 |
1999-11-16 |
Theratech, Inc. |
Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
|
US6040305A
(en)
|
1996-09-13 |
2000-03-21 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US5945429A
(en)
|
1996-09-13 |
1999-08-31 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6030982A
(en)
|
1996-09-13 |
2000-02-29 |
Schering Corporationm |
Compounds useful for inhibition of farnesyl protein transferase
|
JP2001501471A
(ja)
|
1996-09-24 |
2001-02-06 |
メルク エンド カンパニー インコーポレーテッド |
血管新生の阻害のための遺伝子治療
|
US5885834A
(en)
|
1996-09-30 |
1999-03-23 |
Epstein; Paul M. |
Antisense oligodeoxynucleotide against phosphodiesterase
|
EP1007012A4
(en)
|
1996-10-01 |
2006-01-18 |
Cima Labs Inc |
TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
ATE387495T1
(de)
|
1996-12-03 |
2008-03-15 |
Amgen Fremont Inc |
Vollkommen humane antikörper die egfr binden
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
US5939439A
(en)
|
1996-12-30 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6013662A
(en)
|
1996-12-30 |
2000-01-11 |
Rhone-Poulenc Rorer S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
US6093737A
(en)
|
1996-12-30 |
2000-07-25 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2277801C
(en)
|
1997-01-16 |
2002-10-15 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
JP2001509156A
(ja)
|
1997-01-29 |
2001-07-10 |
ゼネカ・リミテッド |
ファルネシルプロテイントランスフェラーゼの阻害剤
|
US5860957A
(en)
|
1997-02-07 |
1999-01-19 |
Sarcos, Inc. |
Multipathway electronically-controlled drug delivery system
|
ZA981080B
(en)
|
1997-02-11 |
1998-08-12 |
Warner Lambert Co |
Bicyclic inhibitors of protein farnesyl transferase
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
US20060246483A1
(en)
|
1997-03-07 |
2006-11-02 |
Rosen Craig A |
337 human secreted proteins
|
US20070015696A1
(en)
|
1997-03-07 |
2007-01-18 |
Rosen Craig A |
621 human secreted proteins
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
US7368531B2
(en)
|
1997-03-07 |
2008-05-06 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
US7411051B2
(en)
|
1997-03-07 |
2008-08-12 |
Human Genome Sciences, Inc. |
Antibodies to HDPPA04 polypeptide
|
US20070055056A1
(en)
|
1997-03-07 |
2007-03-08 |
Rosen Craig A |
251 human secreted proteins
|
US7968689B2
(en)
|
1997-03-07 |
2011-06-28 |
Human Genome Sciences, Inc. |
Antibodies to HSDEK49 polypeptides
|
US20060223088A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Human secreted proteins
|
US20060223090A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Polynucleotides encoding human secreted proteins
|
US20080103090A1
(en)
|
1997-03-07 |
2008-05-01 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
TW591030B
(en)
|
1997-03-10 |
2004-06-11 |
Janssen Pharmaceutica Nv |
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
TR199902553T2
(xx)
|
1997-04-14 |
2000-03-21 |
Micromet Gesellschaft F�R Biomedizinische Forschung Mbh |
�nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6228865B1
(en)
|
1997-06-17 |
2001-05-08 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6239140B1
(en)
|
1997-06-17 |
2001-05-29 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6225322B1
(en)
|
1997-06-17 |
2001-05-01 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6159984A
(en)
|
1997-06-17 |
2000-12-12 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
US6051582A
(en)
|
1997-06-17 |
2000-04-18 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6211193B1
(en)
|
1997-06-17 |
2001-04-03 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
CN1651919A
(zh)
|
1997-06-20 |
2005-08-10 |
拜奥根有限公司 |
结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途
|
US6075007A
(en)
|
1997-07-17 |
2000-06-13 |
Regeneron Pharmaceuticals, Inc. |
Modified noggin polypeptide and compositions
|
AR013184A1
(es)
|
1997-07-18 |
2000-12-13 |
Astrazeneca Ab |
Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
|
DK1011648T4
(da)
|
1997-08-15 |
2005-10-24 |
Cephalon Inc |
Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer
|
US5948433A
(en)
|
1997-08-21 |
1999-09-07 |
Bertek, Inc. |
Transdermal patch
|
DE19821060A1
(de)
|
1997-09-23 |
1999-04-15 |
Bundesrepublik Deutschland Let |
Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
|
AU752433B2
(en)
|
1997-09-23 |
2002-09-19 |
Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts |
Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
US6103723A
(en)
|
1997-10-17 |
2000-08-15 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU9453098A
(en)
|
1997-10-22 |
1999-05-10 |
Zeneca Limited |
Imidazole derivatives and their use as farnesyl protein transferase inhibit ors
|
US6410539B1
(en)
|
1997-10-22 |
2002-06-25 |
Astrazenca Uk Limited |
Imidazole derivatives and their use as farnesyl protein transferase inhibitors
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
KR100719273B1
(ko)
|
1997-10-28 |
2007-05-18 |
반도 카가쿠 가부시키가이샤 |
피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법
|
ATE384732T1
(de)
|
1997-11-03 |
2008-02-15 |
Human Genome Sciences Inc |
Vegi, ein inhibitor der angiogenese und des tumorwachstums
|
US6124465A
(en)
|
1997-11-25 |
2000-09-26 |
Rhone-Poulenc S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
ES2193590T3
(es)
|
1997-11-28 |
2003-11-01 |
Lg Chemical Ltd |
Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos.
|
US6054466A
(en)
|
1997-12-04 |
2000-04-25 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
US6242196B1
(en)
|
1997-12-11 |
2001-06-05 |
Dana-Farber Cancer Institute |
Methods and pharmaceutical compositions for inhibiting tumor cell growth
|
US6335156B1
(en)
|
1997-12-18 |
2002-01-01 |
The Johns Hopkins University School Of Medicine |
14-3-3σ arrests the cell cycle
|
AU745855B2
(en)
|
1998-02-02 |
2002-04-11 |
Lg Chemical Ltd. |
Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
|
BR9908226A
(pt)
|
1998-02-25 |
2000-10-24 |
Lexigen Pharm Corp |
Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
|
WO1999048927A1
(en)
|
1998-03-25 |
1999-09-30 |
Cornell Research Foundation, Inc. |
Methods for designing specific ion channel blockers
|
MXPA00010070A
(es)
|
1998-04-15 |
2004-03-10 |
Lexigen Pharm Corp |
Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
|
CA2328081A1
(en)
|
1998-04-17 |
1999-10-28 |
Lexigen Pharmaceuticals Corporation |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
|
BR9909961A
(pt)
|
1998-04-27 |
2000-12-26 |
Warner Lambert Co |
Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
JP2002518432A
(ja)
|
1998-06-24 |
2002-06-25 |
アドバンスト インハレーション リサーチ,インコーポレイテッド |
吸入器から放出される大多孔性粒子
|
TR200003882T2
(tr)
|
1998-07-06 |
2001-06-21 |
Janssen Pharmaceutica N.V. |
Artropatilerin tedavisi için farnesil protein transferaz inhibitörleri.
|
US6034053A
(en)
|
1998-07-13 |
2000-03-07 |
Wayne Hughes Institute |
EGF-isoflavone conjugates for the prevention of restenosis
|
US6696550B2
(en)
|
1998-07-23 |
2004-02-24 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-CCR2 antibodies and methods of use therefor
|
DK1107989T3
(da)
|
1998-08-25 |
2010-05-25 |
Merck Patent Gmbh |
Ekspression og eksport af angiostatin og endostatin som immunfusiner
|
US6372747B1
(en)
|
1998-12-18 |
2002-04-16 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
US6362188B1
(en)
|
1998-12-18 |
2002-03-26 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
FR2787327B1
(fr)
|
1998-12-21 |
2003-01-17 |
Aventis Pharma Sa |
Compositions contenant des inhibiteurs de farnesyle transferase
|
US6432959B1
(en)
|
1998-12-23 |
2002-08-13 |
Schering Corporation |
Inhibitors of farnesyl-protein transferase
|
CN1341121A
(zh)
|
1999-01-07 |
2002-03-20 |
利思进药品公司 |
作为Fc融和蛋白之抗肥胖蛋白质的表达和外运
|
EP1140938B1
(en)
|
1999-01-11 |
2003-08-27 |
Princeton University |
High affinity inhibitors for target validation and uses thereof
|
MXPA01007163A
(es)
|
1999-01-15 |
2002-03-27 |
Biogen Inc |
Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
|
US6399633B1
(en)
|
1999-02-01 |
2002-06-04 |
Aventis Pharmaceuticals Inc. |
Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
|
DK1156823T3
(da)
|
1999-02-12 |
2009-01-19 |
Scripps Research Inst |
Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
|
US6245759B1
(en)
|
1999-03-11 |
2001-06-12 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
GB9907965D0
(en)
|
1999-04-09 |
1999-06-02 |
Glaxo Group Ltd |
Medical use
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
US6143766A
(en)
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
JP4926320B2
(ja)
|
1999-04-28 |
2012-05-09 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
Vegfの選択的阻害による癌処置のための組成物および方法
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
US6256533B1
(en)
|
1999-06-09 |
2001-07-03 |
The Procter & Gamble Company |
Apparatus and method for using an intracutaneous microneedle array
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
US7129338B1
(en)
|
1999-07-08 |
2006-10-31 |
Research Association For Biotechnology |
Secretory protein or membrane protein
|
EP1514933A1
(en)
|
1999-07-08 |
2005-03-16 |
Research Association for Biotechnology |
Secretory protein or membrane protein
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
AU778611B2
(en)
|
1999-08-09 |
2004-12-16 |
Merck Patent Gmbh |
Multiple cytokine-antibody complexes
|
DE60033530T2
(de)
|
1999-08-24 |
2007-10-31 |
Medarex Inc. |
Humane antikörper gegen ctla-4 und deren verwendungen
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
US20030119038A1
(en)
|
1999-09-09 |
2003-06-26 |
Bingham Brendan William |
NARC1, novel subtilase-like homologs
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
US20100291099A1
(en)
|
1999-09-27 |
2010-11-18 |
Millennium Pharmaceuticals, Inc. |
Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
|
EP1226243A2
(en)
|
1999-10-22 |
2002-07-31 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules derived from rat brain and programmed cell death models
|
US20020081679A1
(en)
|
1999-10-22 |
2002-06-27 |
Millennium Pharmaceuticals, Inc. |
NARC8 programmed cell-death-associated molecules and uses thereof
|
US20110230392A1
(en)
|
1999-10-22 |
2011-09-22 |
Millennium Pharmaceuticals, Inc. |
Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
|
PT1233987E
(pt)
|
1999-11-29 |
2009-12-28 |
Bac Ip B V |
Imobilização de moléculas de ligação ao antigénio de um domínio
|
TWI263496B
(en)
|
1999-12-10 |
2006-10-11 |
Novartis Ag |
Pharmaceutical combinations and their use in treating gastrointestinal disorders
|
US6403581B1
(en)
|
2000-01-19 |
2002-06-11 |
American Cyanamid Company |
Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
|
AU2001241461A1
(en)
|
2000-02-07 |
2001-08-14 |
Millennium Pharmaceuticals, Inc. |
Narc-1, novel subtilase-like homologs
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
US6261595B1
(en)
|
2000-02-29 |
2001-07-17 |
Zars, Inc. |
Transdermal drug patch with attached pocket for controlled heating device
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
US6680315B2
(en)
|
2000-06-15 |
2004-01-20 |
Synta Pharmaceuticals Corp. |
Triazine compounds
|
CA2411971A1
(en)
|
2000-06-16 |
2001-12-27 |
Incyte Genomics, Inc. |
Proteases
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
RU2272644C2
(ru)
|
2000-06-29 |
2006-03-27 |
Мерк Патент Гмбх |
Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
|
WO2002014358A2
(en)
|
2000-08-11 |
2002-02-21 |
Eli Lilly And Company |
Novel secreted proteins and their uses
|
CN1203857C
(zh)
|
2000-09-18 |
2005-06-01 |
威克斯医药有限公司 |
局部麻醉与镇痛的新方法
|
CN1284536C
(zh)
|
2000-09-18 |
2006-11-15 |
威克斯医药有限公司 |
河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
|
US20020064555A1
(en)
|
2000-09-29 |
2002-05-30 |
Dan Cullen |
Proton pump inhibitor formulation
|
DK1324776T4
(en)
|
2000-10-12 |
2018-05-28 |
Genentech Inc |
CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
|
WO2002046383A2
(en)
|
2000-12-08 |
2002-06-13 |
Incyte Genomics, Inc. |
Protein modification and maintenance molecules
|
BR0116803A
(pt)
|
2001-01-18 |
2004-02-17 |
Merck Patent Gmbh |
Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
|
US7189830B2
(en)
|
2001-02-19 |
2007-03-13 |
Merck Patent Gmbh |
Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
PL206701B1
(pl)
|
2001-03-07 |
2010-09-30 |
Merck Patent Gmbh |
Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
|
EP1414845A4
(en)
|
2001-03-21 |
2009-07-08 |
Human Genome Sciences |
SEPARATE HUMAN PROTEINS
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
AU2002258941A1
(en)
|
2001-04-20 |
2002-11-05 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing cell responsiveness
|
DE60239454D1
(de)
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
ES2302811T3
(es)
|
2001-05-23 |
2008-08-01 |
Bristol-Myers Squibb Company |
Procedimiento para proteger transplantes de islotes alogenicos usando moleculas mutantes soblules ctla4.
|
US20040023243A1
(en)
|
2001-06-13 |
2004-02-05 |
Yue Henry |
Proteases
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
US20030124149A1
(en)
|
2001-07-06 |
2003-07-03 |
Shalaby Shalaby W. |
Bioactive absorbable microparticles as therapeutic vaccines
|
US20040038242A1
(en)
|
2001-07-30 |
2004-02-26 |
Edmonds Brian Taylor |
Novel secreted proteins and their uses
|
WO2003015697A2
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
WO2003039592A2
(de)
|
2001-11-09 |
2003-05-15 |
Medigene Aktiengesellschaft |
Zelluläre impfstoffe mit adjuvanzien
|
BR0214650A
(pt)
|
2001-12-04 |
2005-05-03 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
WO2003050531A2
(en)
|
2001-12-11 |
2003-06-19 |
Algonomics N.V. |
Method for displaying loops from immunoglobulin domains in different contexts
|
WO2003059245A2
(en)
*
|
2001-12-18 |
2003-07-24 |
J & J Research Pty Ltd |
Method of treating asthma
|
US20060093771A1
(en)
|
2002-02-15 |
2006-05-04 |
Frantisek Rypacek |
Polymer coating for medical devices
|
US7659082B2
(en)
|
2002-02-19 |
2010-02-09 |
Xenon Pharmaceuticals Inc. |
Methods for identifying analgesic agents
|
US20040110226A1
(en)
*
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
EP2243493A1
(en)
|
2002-07-03 |
2010-10-27 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiative composition
|
US6875433B2
(en)
|
2002-08-23 |
2005-04-05 |
The United States Of America As Represented By The Secretary Of The Army |
Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
ES2374068T3
(es)
|
2002-12-03 |
2012-02-13 |
Ucb Pharma, S.A. |
Ensayo para identificar células productoras de anticuerpos.
|
MXPA05006384A
(es)
|
2002-12-17 |
2005-08-29 |
Merck Patent Gmbh |
Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
|
CA2511823A1
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
US7608260B2
(en)
|
2003-01-06 |
2009-10-27 |
Medimmune, Llc |
Stabilized immunoglobulins
|
WO2004094613A2
(en)
|
2003-04-22 |
2004-11-04 |
Ibc Pharmaceuticals |
Polyvalent protein complex
|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
MXPA05012571A
(es)
|
2003-05-21 |
2006-02-08 |
Medarex Inc |
Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
JP2007501021A
(ja)
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
US7354578B2
(en)
|
2003-06-06 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with VEGF inhibitors
|
GB0315457D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
PT1644412E
(pt)
|
2003-07-01 |
2015-12-23 |
Ucb Biopharma Sprl |
Fragmentos de anticorpos fab modificados
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
CA2537055A1
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US20050118625A1
(en)
|
2003-10-02 |
2005-06-02 |
Mounts William M. |
Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
|
JP2005130764A
(ja)
|
2003-10-30 |
2005-05-26 |
Pharmaceuticals & Medical Devices Agency |
Narc−1遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
|
AU2004309050B2
(en)
|
2003-12-30 |
2010-10-14 |
Merck Patent Gmbh |
IL-7 fusion proteins
|
BRPI0417916A
(pt)
|
2003-12-31 |
2007-04-10 |
Merck Patent Gmbh |
proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
|
US8420087B2
(en)
|
2004-01-05 |
2013-04-16 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
WO2005091956A2
(en)
|
2004-03-05 |
2005-10-06 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
WO2005094879A2
(en)
*
|
2004-03-23 |
2005-10-13 |
Amgen, Inc. |
Monoclonal antibodies specific for human ox40l (cd 134l)
|
US7998481B2
(en)
|
2004-04-05 |
2011-08-16 |
The Regents Of The University Of California |
Modulation of NKG2D for treating or preventing solid organ allograft rejection
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
GB0411186D0
(en)
|
2004-05-19 |
2004-06-23 |
Celltech R&D Ltd |
Biological products
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
GB0412986D0
(en)
|
2004-06-10 |
2004-07-14 |
Xention Discovery Ltd |
Compounds
|
US20050281822A1
(en)
|
2004-06-18 |
2005-12-22 |
Cedarbaum Jesse M |
Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
|
CA2572684A1
(en)
|
2004-06-29 |
2006-01-12 |
The Johns Hopkins University |
Amelioration of drug-induced toxicity
|
CN101023102B
(zh)
|
2004-09-17 |
2013-05-29 |
霍夫曼-拉罗奇有限公司 |
抗-ox40l抗体
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
US7892540B2
(en)
|
2004-10-06 |
2011-02-22 |
Mayo Foundation For Medical Education And Research |
B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
|
EP1819728B1
(en)
|
2004-12-09 |
2010-04-21 |
MERCK PATENT GmbH |
Il-7 variants with reduced immunogenicity
|
KR101017301B1
(ko)
|
2004-12-21 |
2011-02-28 |
메드임뮨 리미티드 |
앤지오포이에틴-2에 대한 항체 및 그의 용도
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
CN102178953A
(zh)
|
2005-02-14 |
2011-09-14 |
惠氏公司 |
白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
|
WO2006091899A2
(en)
|
2005-02-24 |
2006-08-31 |
Amgen Inc. |
Epidermal growth factor receptor mutations
|
AU2006223314A1
(en)
|
2005-03-11 |
2006-09-21 |
Regeneron Pharmaceuticals, Inc. |
Treating anemia by inhibition of VEGF
|
SI2161336T1
(sl)
|
2005-05-09 |
2013-11-29 |
Ono Pharmaceutical Co., Ltd. |
Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
|
NZ564243A
(en)
|
2005-06-08 |
2011-03-31 |
Dana Farber Cancer Inst Inc |
Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway
|
BRPI0613361A2
(pt)
|
2005-07-01 |
2011-01-04 |
Medarex Inc |
anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
|
RU2414924C2
(ru)
|
2005-08-12 |
2011-03-27 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения заболеваний антагонистами vegf
|
GB0517487D0
(en)
|
2005-08-26 |
2005-10-05 |
Isis Innovation |
Antibodies
|
US7972813B2
(en)
|
2005-09-30 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Tetrodotoxin-resistant sodium channel alpha subunit
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
AR057253A1
(es)
|
2005-12-16 |
2007-11-21 |
Genentech Inc |
Anticuerpos anti-ox40l y metodos que los utilizan
|
PL1969007T4
(pl)
|
2005-12-20 |
2014-04-30 |
Bristol Myers Squibb Co |
Kompozycje i sposoby wytwarzania kompozycji
|
WO2007109324A2
(en)
|
2006-03-21 |
2007-09-27 |
Xenon Pharmaceuticals, Inc. |
Potent and selective nav 1.7 sodium channel blockers
|
EP2007423A2
(en)
|
2006-04-05 |
2008-12-31 |
Pfizer Products Incorporated |
Ctla4 antibody combination therapy
|
WO2007128121A1
(en)
|
2006-05-08 |
2007-11-15 |
Adaerata, Limited Partnership |
Chimeric pcsk9 proteins, cells comprising same, and assays using same
|
EP3249052B1
(en)
|
2006-05-11 |
2019-04-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
CA2656700A1
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
ES2439994T3
(es)
|
2006-08-28 |
2014-01-27 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
US20100068194A1
(en)
|
2006-10-24 |
2010-03-18 |
Dong-Ku Kim |
Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
|
US20100136028A1
(en)
|
2006-11-07 |
2010-06-03 |
Sparrow Carl P |
Antagonists of pcsk9
|
CA2668131A1
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
CA2667989A1
(en)
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
CA2667869A1
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
CN101663323A
(zh)
|
2006-12-27 |
2010-03-03 |
埃默里大学 |
用于治疗传染病和肿瘤的组合物和方法
|
CN101600457B
(zh)
|
2007-01-09 |
2014-01-08 |
惠氏公司 |
抗il-13抗体调配物和其用途
|
WO2008090958A1
(ja)
|
2007-01-24 |
2008-07-31 |
Kyowa Hakko Kirin Co., Ltd. |
ドメイン交換された遺伝子組換え抗体組成物
|
AU2008219666A1
(en)
|
2007-02-27 |
2008-09-04 |
Genentech, Inc. |
Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
|
WO2008109871A2
(en)
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
CN101679527A
(zh)
|
2007-04-13 |
2010-03-24 |
诺瓦提斯公司 |
用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
|
CN101707882A
(zh)
|
2007-04-17 |
2010-05-12 |
伊姆克罗尼责任有限公司 |
PDGFRβ特异性抑制剂
|
WO2008137915A2
(en)
|
2007-05-07 |
2008-11-13 |
Medimmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US20130072665A1
(en)
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
EP2205701A4
(en)
|
2007-10-09 |
2011-10-26 |
Rentech Inc |
SYSTEMS AND METHODS FOR OXIDATION OF SYNTHESIS GAS TARS
|
WO2009055783A2
(en)
|
2007-10-26 |
2009-04-30 |
Schering Corporation |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
US8906356B2
(en)
|
2007-11-05 |
2014-12-09 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
US9176122B2
(en)
|
2008-03-24 |
2015-11-03 |
University Of South Florida |
Biomarkers for predicting response to immunosuppressive therapy
|
HUE036780T2
(hu)
|
2008-04-09 |
2018-07-30 |
Genentech Inc |
Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
|
JP5806110B2
(ja)
|
2008-04-23 |
2015-11-10 |
アムジエン・インコーポレーテツド |
中和プロタンパク質コンベルターゼズブチリシンケクシン9型(pcsk9)変形物及びその使用
|
WO2009141239A1
(en)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
PE20110302A1
(es)
*
|
2008-09-19 |
2011-05-21 |
Hoffmann La Roche |
Formulacion farmaceutica de un anticuerpo contra p-selectina
|
WO2010035012A1
(en)
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
AU2009296392B2
(en)
|
2008-09-26 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
US9403904B2
(en)
*
|
2008-11-07 |
2016-08-02 |
Fabrus, Inc. |
Anti-DLL4 antibodies and uses thereof
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
KR20210060670A
(ko)
|
2008-12-09 |
2021-05-26 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
EP2382722B1
(en)
|
2008-12-23 |
2012-05-30 |
Koninklijke Philips Electronics N.V. |
Combining body-coupled communication and radio frequency communication
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
CN102741287B
(zh)
|
2009-02-17 |
2015-02-18 |
Ucb制药公司 |
对人ox40具有特异性的抗体分子
|
RU2542394C2
(ru)
|
2009-03-24 |
2015-02-20 |
ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. |
Гуманизированные антитела против light и их применение
|
WO2010117448A2
(en)
|
2009-04-05 |
2010-10-14 |
Provenance Biopharmaceuticals Corp. |
Chimeric immunocytokines and methods of use thereof
|
WO2011003780A1
(en)
|
2009-07-06 |
2011-01-13 |
F. Hoffmann-La Roche Ag |
Bi-specific digoxigenin binding antibodies
|
DK3622813T3
(da)
|
2009-07-08 |
2021-05-03 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
EP3381937A3
(en)
|
2009-08-13 |
2018-10-31 |
The Johns Hopkins University |
Methods of modulating immune function
|
AU2010285071A1
(en)
|
2009-08-17 |
2012-02-02 |
Roche Glycart Ag |
Targeted immunoconjugates
|
JP5740772B2
(ja)
|
2009-08-31 |
2015-07-01 |
アイビーシー ファーマスーティカルズ,インコーポレイテッド |
二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用
|
US20120283116A1
(en)
|
2009-09-11 |
2012-11-08 |
Leppert Mark F |
Mutant Sodium Channel Nav1.7 and Methods Related Thereto
|
WO2011037791A1
(en)
|
2009-09-25 |
2011-03-31 |
Merck Sharp & Dohme Corp. |
Antagonists of pcsk9
|
PL2482849T3
(pl)
|
2009-09-30 |
2018-11-30 |
Memorial Sloan-Kettering Cancer Center |
Skojarzona immunoterapia w leczeniu nowotworu
|
CA2778673A1
(en)
|
2009-10-27 |
2011-05-05 |
Karen Margrete Miller |
Function modifying nav 1.7 antibodies
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
AU2010313381A1
(en)
|
2009-10-30 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
AX1 and AX189 PCSK9 antagonists and variants
|
WO2011053665A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
JP2013509194A
(ja)
|
2009-10-30 |
2013-03-14 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ax213およびax132pcsk9アンタゴニストおよびバリアント
|
WO2011053743A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
EP2496600A1
(en)
*
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Methods for affinity maturation-based antibody optimization
|
BR122021025338B1
(pt)
|
2009-11-24 |
2023-03-14 |
Medimmune Limited |
Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
|
WO2011071871A1
(en)
|
2009-12-07 |
2011-06-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for enhancing anti-tumor antibody therapy
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
US8962807B2
(en)
*
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
WO2011097477A1
(en)
|
2010-02-04 |
2011-08-11 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
BR112012022917A2
(pt)
|
2010-03-11 |
2017-01-10 |
Pfizer |
anticorpos com ligação a antígeno dependente de ph
|
EP2371857A1
(en)
|
2010-04-01 |
2011-10-05 |
CSL Behring GmbH |
Factor XII inhibitors for treating interstitial lung disease
|
UY33331A
(es)
|
2010-04-13 |
2011-10-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Proteinas de dominio de armazon basadas en fibronectina que se unen a pcsk9
|
PL3202789T3
(pl)
|
2010-04-16 |
2020-09-21 |
Biogen Ma Inc. |
Przeciwciała anty-vla-4
|
US8486647B2
(en)
|
2010-06-09 |
2013-07-16 |
Regeneron Pharmaceuticals, Inc. |
Neuropeptide release assay for sodium channels
|
US8871996B2
(en)
|
2010-06-09 |
2014-10-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing human voltage-gated sodium channels
|
CN105695415A
(zh)
|
2010-06-17 |
2016-06-22 |
科马布有限公司 |
动物模型及治疗分子
|
CN103221427B
(zh)
|
2010-08-23 |
2016-08-24 |
德克萨斯州立大学董事会 |
抗ox40抗体和使用其的方法
|
TW201215405A
(en)
*
|
2010-08-25 |
2012-04-16 |
Hoffmann La Roche |
Antibodies against IL-18R1 and uses thereof
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
EP3211001B1
(en)
|
2010-12-22 |
2020-10-07 |
The Board of Trustees of the Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
MA34818B1
(fr)
|
2010-12-22 |
2014-01-02 |
Genentech Inc |
Anticorps anti-pcsk9 et procédés d'utilisation
|
EP2665822A1
(en)
|
2011-01-18 |
2013-11-27 |
Amgen Inc. |
Nav1.7 knockout mice and uses thereof
|
BR112013018740A2
(pt)
|
2011-01-28 |
2019-01-08 |
Sanofi Sa |
anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
|
EP2481758A1
(en)
|
2011-01-28 |
2012-08-01 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
KR20130118941A
(ko)
|
2011-02-10 |
2013-10-30 |
로슈 글리카트 아게 |
면역치료법
|
CN105440123B
(zh)
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
CN103562227B
(zh)
|
2011-02-11 |
2016-12-21 |
诺瓦提斯公司 |
Pcsk9拮抗剂
|
WO2012132067A1
(ja)
*
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
CN106279401A
(zh)
|
2011-03-11 |
2017-01-04 |
贝丝以色列女执事医疗中心 |
Cd40片段及其用途
|
EP3147297B1
(en)
|
2011-03-31 |
2018-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies directed against icos and uses thereof
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
US9732196B2
(en)
|
2011-05-10 |
2017-08-15 |
Sabic Global Technologies B.V. |
Adhesive for bonding polyimide resins
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
WO2012162583A1
(en)
|
2011-05-26 |
2012-11-29 |
Ibc Pharmaceuticals, Inc. |
Design and construction of novel multivalent antibodies
|
US9574002B2
(en)
*
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
WO2012170607A2
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Use of pcsk9 antagonists
|
EP2720719A4
(en)
|
2011-06-15 |
2015-12-09 |
Glaxosmithkline Ip No 2 Ltd |
METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS
|
RU2014101501A
(ru)
|
2011-06-20 |
2015-07-27 |
Дженентек, Инк. |
Связывающие pcsk9 полипептиды и способы применения
|
EP2723380B1
(en)
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
CA2840460C
(en)
|
2011-07-11 |
2022-08-16 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to ox40 and their uses
|
EP2731623A1
(en)
|
2011-07-14 |
2014-05-21 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
KR101685262B1
(ko)
*
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ox40 항체 및 이의 사용 방법
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
CN103930444B
(zh)
|
2011-09-16 |
2020-08-04 |
瑞泽恩制药公司 |
用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
|
ES2612935T3
(es)
|
2011-09-19 |
2017-05-19 |
Kymab Limited |
Anticuerpos, dominios variables y cadenas adaptados para su uso en seres humanos
|
SG10201610288TA
(en)
|
2011-10-13 |
2017-02-27 |
Bristol Myers Squibb Co |
Antibody polypeptides that antagonize cd40l
|
CN104136047B
(zh)
*
|
2011-10-26 |
2018-02-06 |
安姆根有限公司 |
减少或消除由暴露于uv光而引起的蛋白质修饰和降解的方法
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
US20130115171A1
(en)
|
2011-11-09 |
2013-05-09 |
Stefan I. McDonough |
Nav1.7-related assays
|
HUE051954T2
(hu)
|
2011-11-28 |
2021-03-29 |
Merck Patent Gmbh |
ANTI-PD-L1 ellenanyagok és alkalmazásaik
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
CA2863818A1
(en)
|
2012-02-06 |
2013-08-15 |
Brendan CURTI |
Cancer treatment and monitoring methods using ox40 agonists
|
US20130315913A1
(en)
|
2012-03-26 |
2013-11-28 |
Sanofi |
Anti-light antibody therapy for inflammatory bowel disease
|
WO2013148284A1
(en)
|
2012-03-29 |
2013-10-03 |
Genentech, Inc. |
Antibodies that bind to a pcsk9 cleavage site and methods of use
|
WO2013172933A1
(en)
|
2012-05-15 |
2013-11-21 |
University Of Southern California |
Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
US20150140005A1
(en)
|
2012-05-17 |
2015-05-21 |
Cyon Therapeutics Inc. |
Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
|
US9102751B2
(en)
|
2012-05-18 |
2015-08-11 |
Janssen Biotech, Inc. |
Huwentoxin-IV variants and methods of use
|
EP3892638A1
(en)
*
|
2012-05-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
WO2013181634A2
(en)
|
2012-05-31 |
2013-12-05 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind pd-l1
|
ES2672974T3
(es)
|
2012-06-01 |
2018-06-19 |
Ibc Pharmaceuticals, Inc. |
Complejos multiméricos con estabilidad in vivo, farmacocinética y eficacia mejoradas
|
JP6290209B2
(ja)
|
2012-08-07 |
2018-03-07 |
ロシュ グリクアート アーゲー |
低下した及び増加したエフェクター機能を有するように操作された2つの抗体を含む組成物。
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
MX2015003416A
(es)
|
2012-09-17 |
2015-10-29 |
Galectin Therapeutics Inc |
Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer.
|
KR101947702B1
(ko)
|
2012-10-04 |
2019-02-14 |
다나-파버 캔서 인스티튜트 인크. |
인간 단클론 항-pd-l1 항체 및 사용 방법
|
CN104968364A
(zh)
|
2012-12-03 |
2015-10-07 |
百时美施贵宝公司 |
强化免疫调变性Fc融合蛋白的抗癌活性
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
CA2897826C
(en)
|
2013-01-09 |
2022-09-27 |
Taylor H. Schreiber |
Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
WO2014160438A1
(en)
|
2013-03-13 |
2014-10-02 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
ES2644022T3
(es)
|
2013-03-14 |
2017-11-27 |
Bristol-Myers Squibb Company |
Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
|
MX2015010749A
(es)
|
2013-03-14 |
2015-11-30 |
Regeneron Pharma |
Anticuerpos humanos para nav1.7.
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
JP6550053B2
(ja)
|
2013-09-11 |
2019-07-24 |
メディミューン リミテッド |
腫瘍を治療するための抗b7−h1抗体
|
GB201316644D0
(en)
|
2013-09-19 |
2013-11-06 |
Kymab Ltd |
Expression vector production & High-Throughput cell screening
|
GB201317622D0
(en)
|
2013-10-04 |
2013-11-20 |
Star Biotechnology Ltd F |
Cancer biomarkers and uses thereof
|
EP3060581A4
(en)
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
WO2015088414A1
(en)
|
2013-12-13 |
2015-06-18 |
Isletone Ab |
Immunomodulatory compositions
|
CN113603788A
(zh)
|
2014-01-15 |
2021-11-05 |
卡德门企业有限公司 |
免疫调节剂
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EP3102595B1
(en)
|
2014-02-06 |
2018-11-07 |
F.Hoffmann-La Roche Ag |
Interleukin-2 fusion proteins and uses thereof
|
GB201403775D0
(en)
*
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US10144778B2
(en)
|
2014-03-12 |
2018-12-04 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
SG11201608106PA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
US20150307620A1
(en)
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
AU2015260962B2
(en)
|
2014-05-13 |
2020-06-11 |
Medimmune Limited |
Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
CA2947932C
(en)
|
2014-05-29 |
2021-03-30 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
KR102003754B1
(ko)
|
2014-07-03 |
2019-07-25 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
DK3309174T3
(da)
|
2014-07-11 |
2022-06-07 |
Ventana Med Syst Inc |
ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
|
WO2016022468A1
(en)
|
2014-08-04 |
2016-02-11 |
Baylor Research Institute |
Antagonistic anti-ox40l antibodies and methods of their use
|
JP6909153B2
(ja)
|
2014-08-05 |
2021-07-28 |
アポロミクス インコーポレイテッド |
抗pd−l1抗体
|
MX2017002229A
(es)
|
2014-08-19 |
2017-05-09 |
Merck Sharp & Dohme |
Anticuerpos anti tigit.
|
PL3186283T3
(pl)
|
2014-08-29 |
2020-05-18 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona z zastosowaniem skierowanej przeciw nowotworowi, opartej na wariancie IL2 immunocytokiny oraz przeciwciał przeciwko ludzkiemu ligandowi programowanej śmierci PD-L1
|
ES2952717T3
(es)
|
2014-10-14 |
2023-11-03 |
Novartis Ag |
Moléculas de anticuerpos contra PD-L1 y usos de las mismas
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Tigitに対する抗体
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
US9512229B2
(en)
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
US9434785B1
(en)
|
2015-04-30 |
2016-09-06 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
|
US20220372153A1
(en)
|
2015-03-03 |
2022-11-24 |
Kymab Limited |
Synergistic combinations of ox40l antibodies for the treatment of gvhd
|
FI3265123T3
(fi)
|
2015-03-03 |
2023-01-31 |
|
Vasta-aineita, käyttöjä & menetelmiä
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
BR112017020054A2
(pt)
|
2015-03-23 |
2018-06-05 |
Jounce Therapeutics Inc |
anticorpos para icos
|
KR102610592B1
(ko)
|
2015-03-30 |
2023-12-07 |
주식회사 에스티큐브 |
당화 pd-l1에 특이적인 항체 및 그의 사용 방법
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Tigit結合劑和彼之用途
|
US10696745B2
(en)
|
2015-06-11 |
2020-06-30 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Anti-PD-L1 antibodies
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
WO2017030823A2
(en)
|
2015-08-14 |
2017-02-23 |
Merck Sharp & Dohme Corp. |
Anti-tigit antibodies
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
CA2997130A1
(en)
|
2015-09-02 |
2017-03-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
|
RU2732591C2
(ru)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Анти-tigit антитела и способы применения
|
UA125062C2
(uk)
|
2015-10-01 |
2022-01-05 |
Потенза Терапеутікс, Інк. |
Анти-tigit антигензв'язуючі білки і способи їх застосування
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
WO2017087547A1
(en)
|
2015-11-17 |
2017-05-26 |
Oncomed Pharmaceuticals, Inc. |
Pd-l1-binding agents and uses thereof
|
AU2016355568A1
(en)
|
2015-11-18 |
2018-06-21 |
Merck Sharp & Dohme Llc |
PD1/CTLA4 Binders
|
CN108350080A
(zh)
|
2015-11-24 |
2018-07-31 |
伊莱利利公司 |
用于癌症的联合疗法
|
CN106939047B
(zh)
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
JP6883590B2
(ja)
|
2016-01-29 |
2021-06-09 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Pd−l1に結合する抗原結合性タンパク質
|
ES2801873T3
(es)
|
2016-03-04 |
2021-01-14 |
Sichuan Kelun Biotech Biopharmaceutical Co Ltd |
Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos
|
DK3455257T3
(da)
|
2016-05-09 |
2021-11-01 |
Igm Biosciences Inc |
Anti-pd-l1-antistoffer
|
CN105968200B
(zh)
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
WO2017213695A1
(en)
|
2016-06-07 |
2017-12-14 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
|
CN109414500B
(zh)
|
2016-06-13 |
2022-02-25 |
奥美药业有限公司 |
治疗和诊断用pd-l1特异性单克隆抗体
|
JP6730466B2
(ja)
|
2016-06-13 |
2020-07-29 |
アイ−エムエービー バイオファーマ ユーエス リミテッド |
抗pd−l1抗体およびその使用
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
RU2756236C2
(ru)
|
2016-06-20 |
2021-09-28 |
Кимаб Лимитед |
PD-L1 специфические антитела
|
ES2858091T3
(es)
|
2016-06-20 |
2021-09-29 |
F Star Therapeutics Ltd |
Moléculas de unión que se unen a PD-L1 y LAG-3
|
WO2018005682A2
(en)
|
2016-06-29 |
2018-01-04 |
Checkpoint Therapeutics, Inc. |
Pd-l1-specific antibodies and methods of using the same
|
MX2019000149A
(es)
|
2016-07-07 |
2019-09-23 |
Iovance Biotherapeutics Inc |
Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
|
US11649289B2
(en)
|
2016-08-04 |
2023-05-16 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-ICOS and anti-PD-1 antibody combination therapy
|
CN107686520B
(zh)
|
2016-08-04 |
2023-01-03 |
信达生物制药(苏州)有限公司 |
抗pd-l1纳米抗体及其应用
|
CA3032806C
(en)
|
2016-08-05 |
2021-04-27 |
Y-Biologics Inc. |
Antibody to programmed death-ligand 1 (pd-l1) and use thereof
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP4269439A3
(en)
|
2016-09-10 |
2024-01-17 |
Yeda Research and Development Co. Ltd |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
CA3037230A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Patent Gmbh |
Diagnostic anti-pd-l1 antibody and use thereof
|
RU2770590C2
(ru)
|
2016-10-30 |
2022-04-18 |
Шанхай Хенлиус Байотек, Инк. |
Антитела против pd-l1 и их варианты
|
HUE057559T2
(hu)
|
2016-11-02 |
2022-06-28 |
Jounce Therapeutics Inc |
PD-1 elleni antitestek és alkalmazásaik
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
WO2018119475A1
(en)
|
2016-12-23 |
2018-06-28 |
Remd Biotherapeutics, Inc. |
Immunotherapy using antibodies that bind programmed death ligand-1 (pd-l1)
|
WO2018136553A1
(en)
|
2017-01-18 |
2018-07-26 |
Genentech, Inc. |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
AU2018231618A1
(en)
|
2017-03-09 |
2019-10-03 |
Genmab A/S |
Antibodies against PD-L1
|
WO2018187191A1
(en)
|
2017-04-03 |
2018-10-11 |
Jounce Therapeutics, Inc |
Compositions and methods for the treatment of cancer
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
WO2018195226A1
(en)
|
2017-04-18 |
2018-10-25 |
R-Pharm Overseas, Inc. |
Anti-pd-l1 antibody and use thereof
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗pdl1抗体、およびその使用方法
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
US10442866B1
(en)
|
2019-01-23 |
2019-10-15 |
Beijing Mabworks Biotech Co. Ltd |
Antibodies binding OX40 and uses thereof
|